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Abstract
Introduction: Fatty liver disease is prevalent in populations with high caloric
intake. Nutritherapeutic approaches are being considered, such as supplementary
Vitamin D3, to improve aspects of metabolic syndrome, namely fatty liver disease,
hyperlipidemia, and insulin resistance associated with obesity.
Methods: We analyzed female LDLR/ and LDLRþ/þ mice on a 10-week
diabetogenic diet for markers of fatty liver disease, metabolic strain, and
inflammation.
Results: The groups on a high fat high sugar diet with supplementary Vitamin D3,
in comparison with the groups on a high fat high sugar diet alone, showed
improved transaminase levels, significantly less hypertriglyceridemia and hyper-
insulinemia, and histologically, there was less pericentral hepatic steatosis. Levels of
non-esterified fatty acids and lipid peroxidation products were significantly lower
in the group supplemented with additional Vitamin D3, as were systemic markers
of inflammation (serum endotoxin and IL-6). M2 macrophage phenotype
predominated in the group supplemented with additional Vitamin D3. Beneficial
changes were observed as early as five weeks’ supplementation with VitaminD3 and
extended to restoration of high fat high sugar diet induced decrease of bonemineral
density.
Conclusion: In summary, Vitamin D3 was a significantly beneficial dietary additive
to blunt a prediabetic phenotype in diet-induced obesity of female LDLR/ and
LDLRþ/þ mice.
Introduction
Obesity is a serious health problem in industrialized
countries. It associates with chronic diseases and cancer [1].
Selective consumption of so-called ‘‘energy dense foods,’’
those rich in fats and sugars, is responsible for a significant
increase in body weight in the population [2]. In man,
‘‘metabolic syndrome’’ describes a complex manifestation
of obesity, encompassing hypertension, dyslipidaemia,
‘‘non-alcoholic’’ fatty liver disease (NAFLD), and
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development of diabetes. NAFLD is strongly associated with
obesity and its metabolic complications and comprises a
disease spectrum ranging from simple steatosis (fatty liver),
through non-alcoholic steatohepatitis (NASH), character-
ized by excessive liver inflammation, to fibrosis. Diabetes
develops from insulin resistance, a relative insufficiency of
insulin-mediated decrease of blood glucose levels.
Mouse models of dietary-induced obesity, including
NAFLD development, appear to adequately model several
of the metabolic abnormalities and heterogeneity evident in
the human metabolic syndrome [3]. Notably, C57BL/6J
mice given a high fat, high carbohydrate diet for fourmonths
exhibited severe pan-lobular steatosis (in the absence of an
inflammatory component), a marked increase in hepatic
triglyceride levels, and profound peripheral insulin
resistance [4].
The first mouse genetic model of familial hyperlipidemia,
the Low-density lipoprotein (LDL) receptor knockout
mouse (LDLR/), has not been widely considered for
characterisation of the metabolic syndrome and complica-
tions. However, the LDLR/mouse model has been viewed
as useful when studying diet-induced obesity and insulin
resistance in the presence of hyperlipidemia [5]. Early
studies [6] showed LDLR/ mice fed a Western-type diet
(high fat and/or high sugar) developed fatty liver and
characteristics of non-alcoholic steatohepatitis and these
findings have since been replicated. Longer term Western-
style diet feeding, especially in the presence of oxidative
stressors such as dietary cholesterol, induces a severe NASH
phenotype in LDLR/mice with histological and biochem-
ical evidence of steatosis, inflammation (with endotoxae-
mia), and hepatic fibrosis [7, 8]. Based on the expression of
these features of metabolic syndrome, the mouse model
appears representative of the phenotype of NASH in obese
humans with metabolic syndrome.
Supplementation of a high fat-olive oil–containing diet
with fish oil was shown to have an antiinflammatory effect in
LDLR/ mice, as evidenced by reduced macrophage
infiltration and inflammatory gene expression in white
adipose tissue [9]. This was associated with reduced liver and
plasma lipids. However, other specific dietary interventions
(low fat, low cholesterol) were insufficient to fully reverse
NASH phenotype expression in male LDLR/ mice after
eight months’ Western Diet [10].
A large prevention study revealed a reduced risk of
developing metabolic syndrome with an increase in Vitamin
D levels [11]. Vitamin D3 exerts an anti-inflammatory
effect [12]. The potential of Vitamin D3 supplements to
ameliorate aspects of disease has been studied in clinical trials:
However, a conclusive, beneficial treatment effect of Vitamin
D3 supplementation was neither found in NAFLD [13], nor in
diabetes [14], nor in lipid profile [15], but doses and duration
of Vitamin D3 supplementation varied widely.
Kitson and Roberts [16] have indicated that Vitamin D
deficiency also closely relates to the severity of NAFLD and is
implicated in the pathogenesis of insulin resistance, a key
factor in the development of NAFLD. Inflammation has
been implicated as a contributing factor to dysregulated
hepatic insulin signaling [17] and steatosis. The anti-
inflammatory and immune-modulatory properties of
Vitamin D are putative mechanisms of its effect on liver
disease progression.
Our previous in vitro study demonstrated a significant
effect of Vitamin D3 in decreasing lipopolysaccharide
(LPS)-induced production of TNFa and TGFb from
macrophages and hepatocytes [18], and justified analyzing
the efficacy of dietary supplementation with Vitamin D3 to
improve biochemical and inflammatory features of
metabolic disease in vivo. So far, only few in vivo studies
using mice have evaluated the effects of dietary Vitamin D3
on measures of inflammation and metabolism: in male
C57Bl/6J mice given a high fat diet (HFD) (60% energy as
fat) on its own or with tenfold the recommended dose of
Vitamin D3 (1000 IU/kg) and an additional (small) oral
dose of Vitamin D3 in soybean oil (25 IU/mouse/day) for
10 weeks, hyperinsulinemia in the HFD group was
normalized in the group receiving Vitamin D3, while
adiponectin was significantly elevated in the Vitamin D3
group compared to the HFD group [19]. The rise in
adiponectin is consistent with an increase in insulin
sensitivity [20]. Similarly, in male Swiss mice fed a HFD
(20% of fat from soy beans) for four weeks, then split into
two groups of which one was given Vitamin D3
supplement (0.05mg/kg diet) for an additional four weeks,
the Vitamin D3 supplemented group showed a decrease in
IL-6 protein and increase of IL-10 protein in epididymal
adipose tissue, an inflammatory signature of an increase in
insulin sensitivity [21]. When male LDLR/ mice were
given a diabetogenic diet, consisting of 35.5% sugar and
36.6% fat for 24 weeks, they developed hepatomegaly,
expressed more TNFa, IL-6 and MCP-1 mRNA in their
livers, had elevated levels of insulin, transaminases, and
hepatic triglycerides when compared to their controls [22].
The aim of this study was to determine the effect of one
dose of dietary Vitamin D3 supplementation on liver
transaminase levels, endotoxin levels, as well as inflamma-
tory mediators and metabolic parameters for the duration of
ten weeks and to probe for an effect as early as five weeks in
female C57Bl/6 mice and LDLR/ mice.
Materials and Methods
Experimental design
Animal experimentation was performed in accordance with
UK Home Office regulations and institutional guidelines.
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The study was periodically reviewed by the ethical review
body of the institution. Mice were housed in a specific
pathogen free barrier facility in groups in ventilated cages
at 218C, 50% humidity, with 12/12 h light/dark cycle, and
had ad libitum access to food and water. Mice were
maintained on 5LF2 (14% protein, 6% fat, 65%
carbohydrate), so-called maintenance diet, containing
1 IU/g Vitamin D3. At three months’ of age, female
LDLR/ and LDLRþ/þ were randomized to two groups
fed ad libitum for five or ten weeks the formulated
(cholesterol free) diet 58R3 (20% protein, 36% fat, 35%
carbohydrate, rich in sucrose), termed DD (diabetogenic
diet) differing in the content of admixed Vitamin D3 (1
vs. 11 IU/g diet) (TestDiet, International Product
Supplies, London, UK). Diets were color coded and
food was replaced weekly. Sixty mice were used in total
and analysed in littermate groups. Gnawing blocks were
added to the cage floor covered with corn cob as bedding
material; nesting material (sizzle pet) was made from
recycled paper. Because male mice behaved aggressively,
leading to diet unrelated variation in energy expenditure,
female mice were taken for a more homogenous analysis
of a response to the diet. There was equal environmental
enhancement for all. Mice were weighed weekly and
handled by the same person. At the end of study, mice
were bled under terminal anesthesia, serum prepared, and
organs saved for further measurements. Analyses were
conducted blinded to the genotypes and treatment. Liver
weights were recorded and expressed as % of body weight.
LDLR/ and the equally in house bred background
strain, C57Bl/6, verified to be LDLRþ/þ (by genotyping),
was used in comparison.
Measurement of metabolic parameters
Activities of liver transaminases AST (aspartate ami-
notransferase) and ALT (alanine aminotransferase)
were determined in serum samples diluted 1:5 follow-
ing the manufacturer’s instructions (Abcam, Cam-
bridge, UK). Non-esterified fatty acids were measured
using NEFA Assay kit from WAKO Chemicals GmbH
(Neuss, Germany). Triglyceride colorimetric assay kit
was from Cayman Chemical (Michigan, USA). Malo-
nedialdehyde and insulin were measured by immuno-
assay kit (Abcam and Biorbyt, Cambridge, UK).
Adiponectin was measured using ELISA Mouse Adi-
ponectin/Acp30 (R&D systems, Abingdon, UK) using
serum in 2000-fold dilution as suggested by the
manufacturer. HbA1c was measured in 1:10 diluted
serum samples using mouse glycated Hemoglobin A1c
ELISA kit as indicated by the supplier (CUSABIO,
Wuhan, China). Mouse 1,25-dihydroxy-Vitamin D3
ELISA kit was from CUSABIO.
Measurement of inflammatory component
Endotoxin was measured by LAL method in serum diluted
1:50 (PierceTM LAL chromogenic endotoxin quantification
kit, ThermoScientific). Murine IL-6 ELISA kit (Peprotech,
London, UK) was used according to manufacturer’s
instructions. Serum dilution was 1:10.
Histopathological assessment
Four micrometer sections were prepared from paraffin
embedded specimens and stained with hematoxylin and
eosin, and evaluated following published criteria [23].
qPCR analysis
RNA was prepared using RNeasy Mini Kit (Qiagen,
Manchester UK), genomic DNA was digested and cDNA
was synthesized using RevertAid H Minus First Strand
cDNA Synthesis Kit (Thermo Fisher Scientific, Lough-
borough, UK). Primer sequences were: for arginase 50-
GGGAATCTGCATGGGCAAC-30, 50-GCAAGCCAATG-
TACACGATGTC-30; iNOS 50-GGCAGGCCTGTGA-
GACCTTTG-30, 50-GAAGCGTTTCGGGATCTGAA-30;
Srebp-1c 50-TCTGCCTTGATGAAGTGTGG-30, 50-AG-
CAGCCCCTAGAACAAACA-30; endogenous reference
gene (GAPDH) 50-CCTGGAGAAACCTGCCAAGTATG-
30, 50-AGAGTGGGAGTTGCTGTTGAAGTC-30. GAPDH
was checked for stability of expression across the dietary
groups before using as endogenous reference gene. The Livak
or 2DDCT method was used to calculate the normalized
expression ratio of target gene and reference gene [24].
Quantification of bone mineral density
Spines from six 3-month-old LDLRþ/þ mice that were fed
for five weeks either the maintenance diet or the
diabetogenic diet (with or without Vitamin D3 supple-
mentation) were studied. Following terminal anesthesia,
the spinal columns were dissected and fixed in 10% formal
saline. All bone samples were stored in PBS at 48C. The
specimens were scanned with a high speed in vivo mCT
scanner (Quantum FX, PerkinElmer Inc.). All images were
acquired blinded to the treatment with the following
parameters: 90 kVp voltage, 80mA current, field of view
(FOV) 5 5mm, and with isotropic resolution of 10mm.
The bone mineral density for the lumbar vertebra L3 was
estimated using a calcium hydroxyapatite (CaHA) phan-
tom (MicroCT-HA, Quality Assurance in Radiology and
Medicine GmbH), scanned using the same parameters as
for the spines. For accurate bone density calibrations,
images of the phantom consisting of six different CaHA
concentrations were analysed. Linear regression of
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measured grayscale values versus known mineral density of
phantom regions (mg HA/cm3) was plotted. The obtained
SigmaCT and BetaCT values were then used for conversion
of X-ray values to quantify real cortical and trabecular
bone density.
Custom software (Analyze 12.0, AnalyzeDirect) was used
for semi-automatic image processing. Firstly, the Volume
Edit tool was used to create a segmentation mask.
Determination of the optimal threshold that excludes soft
tissue but includes only the bone of interest was kept the
same for all samples. The created segmentation mask of the
bone was loaded onto the bone mineral analysis add-on for
determination of cortical and trabecular bone by their
further thresholding and correction steps. The final image
was used as a mask to measure mineral density of cortical
and trabecular bone of the lumbar spines.
Statistical analysis
Gaussian distribution of measurements was assumed. Data
were presented as means SD and analysed by unpaired t-
test using Prism Pad 6. A P-value <0.05 was deemed
significant.
Results
The high fat high sugar diet was palatable for the mice.
LDLRþ/þ and LDLR/ exceeded the normal weight gain of
10–15%over 10weeks ofmaintenance diet by about fourfold
when on a high fat high sugar diet. At the end of the 10-week
feeding period, body weights of the groups fed the
diabetogenic diet (DD) and the groups fed the DD with
additional Vitamin D3 supplementation, were not signifi-
cantly different from one another. Their dietary intakes were
comparable and furs appeared equally matted.
The dose of Vitamin D3 chosen as additive to the high
fat high sugar diet was based on a study of potential
toxicity of Vitamin D3 in mice [25]. At a dose of 0.05mg/
kg body weight/d (equivalent to the additional dose
admixed to the formulated diet (10 IU/g diet) based on a
daily intake of 5 g), mice did not lose weight, maintained
stable calcium levels and generated serum levels of
Vitamin D3 which were significantly below those associ-
ated with hypercalcemia and toxicity. The serum levels of
Vitamin D3 measured in the experimental mice of our
study were even lower than these non-toxic levels
previously reported [25]. Proof that supplementation
with Vitamin D3 yielded elevation in blood levels of
Figure 1. Amelioration of transaminase elevations in LDLRþ/þ (A and B) and LDLR/ (C and D) fed a diabetogenic diet with or without admixed Vitamin
D3 for 10weeks. Dashed line indicates basal level of activities in LDLR
þ/þ or LDLR/ fed a normal, maintenance diet. P0.05, P< 0.005, P< 0.0005.
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Vitamin D3 is given in supplementary Table S1. The lower
levels of Vitamin D3 in serum of LDLR
/ compared to
LDLRþ/þ fed the high fat high sugar diet with Vitamin D3
supplementation is likely to be reflective of greater binding
of Vitamin D3 to lipoproteins which are elevated in
LDLR/ [26, 27]. Mice were subsequently analyzed for
markers of fatty liver disease, metabolic strain, and
inflammation, following the hypothesis of a beneficial
effect of Vitamin D on key corollaries of a continued high
fat high sugar diet.
At our timepoint of 10 weeks, there was no hepatomegaly,
but macroscopic (yellowish discoloration of the liver) and
microscopic signs of fatty liver changes. As observed by
others, there were stark regional differences in manifestation
of fatty liver changes [28].Where these were present, analysis
of the hepatic lobular zones revealed that lipid accumulation
in hepatocytes occurred near the periportal field in LDLRþ/þ
and importantly, near the central vein in LDLR/ fed a high
fat sugar diet, and was improved in the groups given
supplementary Vitamin D3 (supplementary Fig. S1). mRNA
expression of lipogenic transcription factor Strebp-1c was
significantly decreased in livers from both, LDLRþ/þ and
LDLR/ fed a high fat sugar dietwith supplementaryVitamin
D3 compared to their controls (supplementary Fig S1),
demonstrating transcriptional adaptation to the presence of
Vitamin D3 in avoidance of developing steatosis. Hepatic
transaminases as markers of hepatocellular damage were
determined in serum and found to be elevated in mice fed the
high fat high sugar diet (compared to mice fed the
maintenance diet) but significantly lowered in LDLR/ and
LDLRþ/þ mice receiving Vitamin D3 supplemented high fat
high sugar diet (Fig. 1A–D). Importantly, the levels achieved
in Vitamin D3 supplemented groups were not significantly
lower than the levels in mice receiving maintenance diet,
meaning that there were no signs of intervention induced
hepatotoxicity [29].
To gauge the extent glucose control was compromised in
this model, glucose, insulin, adiponectin, and HbA1c levels
were determined. High fat high sugar diet for ten weeks
provoked in LDLRþ/þ and LDLR/ mice elevated levels of
insulin (non fasting blood glucose was not different from
normal, data not shown) and inversely, depressed levels
of adiponectin, which were both close to normal when
additional Vitamin D3 was admixed to the diet (Fig. 2A–D).
Figure 2. Correction of hyperinsulinemia in the presence of Vitamin D3 supplemented to 10 weeks’ diabetogenic diet. Dashed line indicates basal level
of hormones in LDLRþ/þ or LDLR/ fed a normal, maintenance diet. P< 0.005, P< 0.0005, P< 0.0001.
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Serum levels of adiponectin in mice on high fat high
sugar diet were markedly lower than those in mice on
maintenance diet, as expected [30]. HbA1c levels allow
sensitive appraisal of blood glucose levels over the duration
of the 10-week diet (mouse red blood cells have a life span of
40 days). Vitamin D3 supplementation of a high fat high
sugar diet reduced aberrant protein glycosylation (HbA1c
as surrogate marker) significantly for each genotype (supple-
mentary Table S2).
LDLR/ mice had a higher basal triglyceride level than
LDLRþ/þ mice as expected from their deficiency of LDL
receptor and associated defect in lipoprotein clearance
(Fig. 3A and C). LDLRþ/þ and LDLR/ mice developed
significant hypertriglyceridemia at the 10 week-endpoint of
the HFD study. VitaminD3 supplementation of high fat high
sugar diet led to normalization of triglyceride levels in both
genotypes. Similarly, NEFA levels were higher in diet-
stimulated LDLR/ compared to LDLRþ/þ as expected.
Vitamin D3 supplementation led to significantly reduced
levels of NEFA in both genotypes after 10 weeks (Fig. 3B and
D).
Endotoxaemia is a feature of obesity [18]. We found that
10 weeks’ high fat high sugar diet increased endotoxin levels
manifold over levels measured in mice fed a normal diet
(Fig. 4A and C). Vitamin D3 treatment significantly
decreased endotoxin levels in both groups fed a high fat
high sugar diet. The Vitamin D3 supplemented high fat high
sugar diet groups had significantly less MDA, a lipid
peroxidation product, in serum than their counterparts
without additional Vitamin D3 (Fig. 4B and D).
Diabetogenic diets are epidemiologically linked to
inflammation associated with metabolic syndrome [31], so
we next assessed the impact of Vitamin D on markers of a
proinflammatory profile. In the presence of additional
dietary Vitamin D3, there was a decrease in serum levels for
the hepatic master cytokine and adipocytokine, IL-6
(Fig. 5A and B). Analysis of splenic gene expression for
iNOS and arginase-1 revealed a signature consistent with
relative skewing towards M2 type mRNA expression in
groups receiving additional dietary Vitamin D3: a decline of
iNOS expression and inversely an increase of arginase-1
expression in the VitaminD3 supplemented group relative to
the high fat high sugar diet group (Fig. 5C–F).
In an attempt of ‘‘Refinement’’ of our animal experimen-
tation, we analyzed a shortened protocol. A significant
benefit of supplementary Vitamin D3 was seen in LDLR
þ/þ
Figure 3. Serum triglycerides and non-esteriﬁed, free fatty acids in LDLRþ/þ (A and B) and LDLR/ (C and D) fed a diabetogenic diet without or with
additional Vitamin D3 for 10 weeks. Dashed lines in graphs represent levels measured in mice fed the maintenance diet, respectively. P< 0.05,
P< 0.005.
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and LDLR/ mice as early as five weeks when fed a
diabetogenic diet, in terms of serum levels for IL-6, insulin,
and NEFA (Table 1). Of these mice, LDLRþ/þ were used to
investigate the impact of Vitamin D3 supplementation on
bone mineral density. The reduced bone mineral density
seen in LDLRþ/þ mice fed a high fat high sugar diet for five
weeks was normalized in those supplemented with Vitamin
D3.
Discussion
A diet high in fat and sugar is associated with a
proinflammatory systemic reaction, though the exact
mechanistic linkage is far less certain than the epidemiologi-
cal evidence [31]. Generation of oxidized LDL via free
radicals, shift of gut flora to more gram negative species,
translocation of LPS, and elevated free fatty acids are
precipitating factors [32]. Cytokine release from classically
activated, so-called M1, macrophages inhibits insulin
sensitivity [33]. Nutritional interventions using ‘‘food
bioactives,’’ such as omega-3 fatty acids, antioxidative
compounds from plants or Vitamin E, are beginning to
be widely tested in approaches to correct unhealthy
lifestyles [34].
We analyzed female LDLR/ and LDLRþ/þ mice on a 10
week-Western-style (20%protein, 36% fat, 35%carbohydrate,
rich in sucrose) diet for markers of fatty liver disease,
metabolic dysfunction, and inflammation. This study
evaluated the effect of supplemented Vitamin D3 on
steatosis as well as on the metabolic and inflammatory
profile of the experimental mice.
LDLR/ mice were used as an aggravated model of
metabolic strain to identify the scope of beneficial applica-
tion of Vitamin D3. Their baseline levels for triglycerides and
HbA1c were higher than in LDLRþ/þ. Consistent with other
investigators, we have shown that mice lacking the LDL
receptor, when fed a Western-style diet, display many
features of the obesity-related metabolic syndrome, includ-
ing steatosis, insulin resistance, and dyslipidemia [6]. The
present study has confirmed the dysmetabolic and associated
hepatosteatosis changes in LDLR/ female mice fed a high
fat sugar diet.
This is the first study to analyze the development of a diet-
induced prediabetic phenotype and its modulation by
Figure 4. Levels of endotoxin and lipid peroxidation product,MDA, as inﬂammatory agents in serumof LDLRþ/þ and LDLR/ fed a diabetogenic diet for
10 weeks without or with additional supplemented Vitamin D3. Dashed line in A and C represents endotoxin levels measured in mice fed the
maintenance diet. P< 0.05, P< 0.0001.
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Vitamin D in female mice. Within a rodent high fat diet
model of NAFLD, Roth et al. [35] showed that Vitamin D
deficiency exacerbated histologic features of NAFLD,
increased insulin resistance, and upregulated liver tissue
expression of genes involved in hepatic inflammation and
oxidative stress.
As previously described [28], we have demonstrated
regional differences in manifestation of fatty liver. Hepato-
cyte lipid accumulation occurred near the periportal field in
LDLRþ/þmice, near the central vein in LDLR/ fed a high
fat sugar diet for 10 weeks. Our study finds a decrease in
hepatic pericentral steatosis especially in LDLR/ mice
Figure 5. Systemicmeasures of inﬂammation and amelioration in response to additional Vitamin D3 supplemented to a tenweeks’ diabetogenic diet for
serum IL-6 (A and B), iNOS and arginase 1 mRNA expression in spleen (C–F). P< 0.05, P< 0.005, P< 0.0005.
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receiving Vitamin D3 supplementation to their high fat high
sugar diet. mRNA for Srebp-1c, a transcription factor that
regulates genes involved in lipogenesis, was significantly
decreased in both, LDLR/ and LDLRþ/þ, Vitamin D3
supplemented high fat high sugar diet groups. In a study of
male Sprague-Dawley rats, intraperitoneal injections every
other day with 1mg/kg Vitamin D3 during a high fat diet
(45% energy as fat) for 8 weeks led to decreased levels of
triglyceride and fatty acids and improved levels of AST [36].
The mechanism was thought to be inhibition of lipogenesis
and promotion of fatty acid oxidation in liver, based on a
decrease in Srebp-1c mRNA and a concomitant increase of
PPARa mRNA in response to injection of Vitamin D3. In
pronounced fatty liver disease in our study, zone 3 of the
hepatic lobules at the central vein, with lowest oxygen
tension and harboring enzymes that regulate lipogenesis, was
particularly affected. Liver transaminases are elevated in
serum due to hepatocellular damage. While ALT is
predominately expressed in liver, AST is more widely
expressed. ALT and AST were significantly reduced to
normal levels when Vitamin D3 was supplemented to the
high fat high sugar diet. Though the diabetogenic diet was of
comparable composition in the study conducted by
Subramanian et al. [22], steatohepatitis and fibrotic changes
were not a feature in livers obtained from our experimental
animals, which is likely due to the significantly shorter
duration of diet in this study (10 vs. 24 weeks).
A previous study investigating C57Bl6/J mice found no
impact on body weight of dietary Vitamin D3, added at a
comparable dose to this study [19]. Others have described an
effect on weight loss in mice [37], but at significantly higher
dietary intake of Vitamin D3 (10-fold higher from the dose
chosen for this study). A role of Vitamin D3 in metabolism
has been derived from genetically engineered mice deficient
of Vitamin D receptor, in which the lack of cognate signaling
led to proinflammatory alterations linked to development of
insulin resistance [38]. Clinical trials, however, were unable
to establish a benefit of Vitamin D supplementation in
enhancing insulin sensitivity [39]. In our study, supplemen-
tation of a diabetogenic diet with Vitamin D3 led to the
normalisation of insulin levels, which were pathologically
elevated in those mice receiving the diabetogenic diet only.
Levels of adiponectin increased reciprocally. A recent meta-
analysis of six clinical trials showed that Vitamin D
supplementation for an average period of 23 weeks led to
a significant increase of adiponectin levels [40]. VDR and
PPARg interact [41]; the ADIPOQ gene promoter has a
PPARg responsive element [42].
LDLR/ show a decline in the hormonally active
metabolite of Vitamin D3 (1,25-dihydroxy-Vitamin D3) in
response to 10 weeks of high fat high sugar diet. This could
imply interference of the diabetogenic diet with hydroxylase
activities [43] or a redistribution of the lipophilic vita-
min [44]. On the diabetogenic diet, LDLR/, compared to
LDLRþ/þ, mice showed increased levels of triglycerides, free
fatty acids and HbA1c, while endotoxin, MDA, IL-6, and
macrophage polarization were not influenced by the Ldlr
genotype. This is consistent with LDLR/ representing a
primarily metabolically strained mouse model.
This study finds, for the first time, a reversal of iNOS and
arginase-1 expression in the Vitamin D3 treated groups
compared to the high fat high sugar diet groups, indicative of
a beneficial shift towards M2 [41]. A certain metabolic state
associates with certain macrophage activity profiles, the
extremes of which are found in so-called M1 or M2
polarization, and which may differ between adipose and
other tissues. M1 type macrophages are associated with
inflammation and the development of impaired cellular
response to insulin, so-called insulin resistance. M2 type
macrophages are thought to predominate in the lean [45].
The gut microbiome has emerged as an important factor
in development of obesity and metabolic syndrome [46].
However, this study did not analyze the gut microbiome so
cannot comment on the influence of a possible Vitamin D3
induced change in gut flora and associated endotoxin
translocation [47, 48] on the observed phenotype.
Bonemineral density in LDLRþ/þ fed a high fat high sugar
diet for five weeks was significantly decreased relative to the
Vitamin D3 supplemented group, which compared to the
group on maintenance diet. Loss of bone mineral density
due to a diet high in fat has previously been linked to
increased osteoclast activity [49]. Vitamin D, by contrast,
Table 1. Five weeks’ diabetogenic diet with or without supplementation with Vitamin D3.
IL-6 (ng/ml) Insulin (ng/ml) NEFA (mmol/L) Bone mineral density (mg/cc)
LDLRþ/þ DD 1.86 0.10 (n¼ 7) 1.94 0.27 (n¼ 7) 0.28 0.06 (n¼ 4) 2183.4 18.7 (n¼ 2)
LDLRþ/þ DDþVD 0.79 0.11 (n¼ 10) 1.21 0.33 (n¼ 10) 0.08 0.02 (n¼ 5) 2321.1 34.9 (n¼ 2) [baseline
LDLRþ/þ 2371.3 39.6, n¼ 2]
LDLR/ DD 2.3 0.21 (n¼ 4) 2.19 0.06 (n¼ 4) 0.24 0.03 (n¼ 2) n.d.
LDLR/ DDþVD 0.75 0.09 (n¼ 5) 0.99 0.41 (n¼ 4) 0.15 0.01 (n¼ 2) n.d.
Mean SD are indicated; P< 0.0001,  P< 0.0005, P< 0.005, P< 0.05 compared to genotype matched DD group (unpaired t-tests).
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acts by counterregulating osteoblast activity [50]. However,
concomitant changes in lipid oxidation products, of which
MDA is a surrogate maker, are likely to impact directly
on osteoblasts and osteoclasts as so-called bioactive
inflammatory lipids [51]. Studies of the bone mineral
density in LDLR/ fed a high fat high sugar diet are
currently under way.
In conclusion, this work further supports the use of the
LDL receptor knockout mouse as a useful model for
studying the metabolic complications of diet-induced
obesity and insulin resistance in the presence of hyperlip-
idemia. In this study, Vitamin D3 supplementation
significantly reduced the expression of the metabolic
syndrome phenotype, notably progression of NAFLD,
within dietary-induced obesity among female LDLR/
and LDLRþ/þ mice. Therefore, this study strengthens the
use of Vitamin D3 as a so-called nutraceutical [52]—a
dietary supplement with proven effect on health—because
of its normalising action on lipid levels, glucose control,
and systemic inflammation markers in mice fed a high fat
high sugar, diabetogenic diet.
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Figure S1. Macrovesicular steatosis (A, B and D) especially
near CV (zone 3) in LDLR/ (A).
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